Day: March 26, 2020

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICESCALGARY, Alberta, March 26, 2020 (GLOBE NEWSWIRE) — Bluewater Acquisition Corp. (TSXV: BAQ.P) (“Bluewater“), a capital pool company with the aim of identifying and investing in assets and businesses in the maritime/shipping sector, announces the following changes to the officers and directors of Bluewater. Peter Karos has resigned as Chief Executive Officer and Director of Bluewater.  Mihalis Sapountzoglou is appointed as Chief Executive Officer and will continue to serve as Bluewater’s Chief Financial Officer.Antonios Backos is appointed as Chief Operating Officer.Mr. Karos will continue to work closely with Bluewater and will be joining Frederick Jones as a special advisor to the board and management of Bluewater.  Peter’s knowledge and...

HAMPTON, N.J., March 26, 2020 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2019.“We are pleased that Celldex entered 2020 with significant momentum, following exciting data in late 2019 from the CDX-1140 program that suggest this candidate is a best in class CD40 agonist,” said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. “We are actively recruiting patients across multiple expansion cohorts to further explore potential indications and new combination approaches. We also continue to advance the Phase 2 program of our ErbB3 inhibitor, CDX-3379, exploring a potential biomarker strategy in head and neck squamous cell carcinoma.”“Last month, we completed dosing in the Phase...

BURNABY, British Columbia, March 26, 2020 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 63,200 share options. All of the foregoing share options were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of March 25, 2020 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).The share options have an exercise price of $11.25 per common share, which is equal to the closing price per share of Xenon’s common shares on the grant date of March 25, 2020. The shares underlying the options vest over four years, with 25% vesting on the one-year...

DALLAS, March 26, 2020 (GLOBE NEWSWIRE) — Capital Southwest Corporation (“Capital Southwest” or the “Company”; Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, today announced the Company will withdraw its voluntary redemption of $35,000,000 in principal of the $77,136,175 in aggregate principal amount of issued and outstanding 5.95% Notes due 2022 (the “December 2022 Notes”) previously scheduled to be redeemed on April 3, 2020. Bowen Diehl, Chief Executive Officer, commented, “As everyone is aware, the world is suffering through a pandemic which is causing extreme disruptions to the U.S. and global economy and financial markets at least for the near term.  The full extent of the economic impact,...

Company to host conference call and webcast today at 5:00 p.m. EDT / 2:00 p.m. PDTSAN DIEGO, March 26, 2020 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced fourth quarter and full year 2019 results and provided a corporate update.“2019 was a productive year for aTyr and we achieved some key milestones, including the announcement of interim safety data results for our ongoing ATYR1923 Phase 1b/2a clinical trial for patients with pulmonary sarcoidosis. We also recently entered into a licensing collaboration with Kyorin Pharmaceutical Co., Ltd. (Kyorin) and received an $8.0 million upfront payment. Including our efforts related to neuropilin-2 (NRP2) receptor biology, we believe these...

BASKING RIDGE, N.J., March 26, 2020 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointments of three new independent members to its Board of Directors effective April 2, 2020. The newly appointed board members are John Gandolfo, Thomas Patton and Peter Cuneo. The company also announced that current Board members Nick Colucci and Jim Tullis will be stepping down from the Board prior to the company’s annual meeting of stockholders that is expected to be held in June 2020.  As previously announced Chairman Carrie S. Cox is stepping down from the Board on April 1, 2020 and will be succeeded in that role by independent Board member Michael G. Atieh.“John, Tom and Peter are all successful organizational leaders with proven track records, and I am very pleased...

Conference Call scheduled for today, March 26th at 4:30 p.m. ETAUSTIN, Texas, March 26, 2020 (GLOBE NEWSWIRE) — Vermillion, Inc. (Nasdaq: VRML), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the fourth quarter and year ended December 31, 2019.“We are very pleased with the overall business momentum we created in 2019 and the continued growth into 2020. We have also implemented strategies to help manage the impact on our business of the COVID-19 pandemic and actions taken to contain it,” stated Valerie Palmieri, President and CEO of Vermillion. “Our team is focused on emerging from COVID-19 even stronger, with an increase in the use of virtual sales tools, as well as a deep product pipeline to address the entire patient life cycle, from endometriosis to ovarian...